(MedPage Today) — CHICAGO — The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for phlebotomy among polycythemia vera patients who had been dependent on it, the VERIFY phase III trial showed…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115864
Author :
Publish date : 2025-06-02 19:58:00
Copyright for syndicated content belongs to the linked Source.
